Early clinical trials included many subtypes of non-Hodgkin’s lymphoma including several T-cell lymphomas suggested some promising signals.4 Prior studies demonstrated that selinexor blocked the nuclear export of several transcription factors and increased the expression of the PD-1 in normal leukocytes and PD-L1 in tumor cell lines, which may sensitize the activities of ICIs. The gene discussed is CD274; the disease is neoplasm.